SAGE Therapeutics Inc (SAGE.OQ)
* SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:
* Sage Therapeutics announces proposed public offering of common stock
Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.
Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies, sending shares of the company up about 17 percent in pre-market trade.
Nov 9 Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.
* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression
* Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update
The major Wall Street indexes hit record closing highs on Tuesday, with financial stocks leading the charge, but gains were stunted by a decline in Apple Inc shares after it unveiled its latest line of iPhones. | Video
The S&P 500 hit a record intraday high on Tuesday, led by gains in financial and industrial stocks after Irma weakened to a tropical depression, but declines in McDonald's and technology stocks weighed on the Dow and Nasdaq.
Sage Therapeutics Inc's shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.